The envelope glycoprotein-120 (gp-120) is the most studied target, and the attempt to use T cells targeting gp-120 to treat HIV infection started as early as 1991.112 Currently, promising results have been achieved in anti-HIV infection CAR T therapy.113–115 In addition, HIV infection of CD4-positive T cells has been well solved by gene editing methods.115 The HIV virus is unstable and can easily escape single-target treatment. This evidence concerns the gene CD4 and HIV infectious disease.